Georg Gelbenegger

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 11

Top Topics

Atrial Fibrillation

Antiplatelet Therapy

Chronic Lymphocytic Leukemia

Cardiovascular Disease

Top Venues

Expert opinion on biological therapy

Expert review of clinical pharmacology

Thrombosis journal

This page only lists publications with an associated author ORCID identifier.

Publications

Felix Bergmann, Lena Pracher, Rebecca Sawodny, Amelie Blaschke, Georg Gelbenegger, Christine Radtke, Markus Zeitlinger, Anselm Jorda
Efficacy and Safety of Corticosteroid Therapy for Community-Acquired Pneumonia: A Meta-Analysis and Meta-Regression of Randomized, Controlled Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Georg Gelbenegger, Sigbjørn Berentsen, Bernd Jilma
Monoclonal antibodies for treatment of cold agglutinin disease. Expert opinion on biological therapy (2023)
Georg Gelbenegger, Sigbjørn Berentsen, Bernd Jilma
Monoclonal antibodies for treatment of cold agglutinin disease. Expert opinion on biological therapy (2023)
Georg Gelbenegger, Ludwig Traby, Nina Rahimi, Paul Knöbl
Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis. British journal of clinical pharmacology (2022)
Georg Gelbenegger, Juergen Grafeneder, Gloria M Gager, Jolanta M Siller-Matula, Michael Schwameis, Bernd Jilma, Christian Schoergenhofer
Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial. Thrombosis journal 20 (1) (2022)
Cihan Ay, Katarina D Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, Christa Ulrike Firbas, Peter Quehenberger, Petra Jilma-Stohlawetz, James C Gilbert, Shuhao Zhu, Martin Beliveau, Franz Koenig, Alfonso Iorio, Bernd Jilma, Ulla Derhaschnig, Ingrid Pabinger
von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. Blood (2022)
Georg Gelbenegger, Ulrich Jaeger, Michael Fillitz, Shirley D'Sa, Ronwyn Cartwright, Frank Shafer, Marek Wardȩcki, Jennifer Wang, Christian Schoergenhofer, Bernd Jilma
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial. British journal of haematology 198 (4) (2022)
Georg Gelbenegger, Ulrich Jäger, Michael Fillitz, Christian Schoergenhofer, Christian Sillaber, Bernd Jilma
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease. Blood advances (2022)
Georg Gelbenegger, Bernd Jilma
Clinical pharmacology of antiplatelet drugs. Expert review of clinical pharmacology 15 (10) (2022)
Cihan Ay, Ingrid Pabinger, Katarina D Kovacevic, Georg Gelbenegger, Christian Schörgenhofer, Peter Quehenberger, Petra Jilma-Stohlawetz, Raute Sunder-Plassmann, James C Gilbert, Shuhao Zhu, Bernd Jilma, Ulla Derhaschnig
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood advances 6 (18) (2022)
Georg Gelbenegger, Marek Postula, Ladislav Pecen, Sigrun Halvorsen, Maciej Lesiak, Christian Schoergenhofer, Bernd Jilma, Christian Hengstenberg, Jolanta M Siller-Matula
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC medicine 17 (1) (2019)